Evidence map›Paper›PMID 19788504›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2010

Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection.

A J Booth, K Csencsits-Smith, S C Wood, G Lu, K E Lipson, D K Bishop

Open access · bronzeAbstract read
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. IL-6 Directed Therapy in Transplantation.Current transplantation reports · 2021
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Impact of Human Mutant TGFβ1/Fc Protein on Memory and Regulatory T Cell Homeostasis Following Lymphodepletion in Nonhuman Primates.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2016
    Article
  14. Article
  15. Article
  16. Article
  17. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation.American journal of respiratory and critical care medicine · 2012
    Article
  18. Review
  19. Article
  20. IL-6 promotes cardiac graft rejection mediated by CD4+ cells.Journal of immunology (Baltimore, Md. : 1950) · 2011
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

A J BoothGraduate Program in Immunology, University of Michigan Medical Center, Ann Arbor, MI, USA.
K Csencsits-Smith
S C Wood
G Lu
K E Lipson
D K Bishop
University of Michigan–Ann Arbor · USFibroGen (United States) · USInstitute of Immunology · HRThe University of Texas Health Science Center at Houston · US

Funding

Therapeutic Targets for Chronic Allograft RejectionR01HL070613 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BISHOP, D. KEITH · 2002 to 2014
$4.4M
Roles of CD40 and CD40 Ligand in Allograft RejectionR01AI061469 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BISHOP, D. KEITH · 2004 to 2008
$1.6M
NHLBI NIH HHS R01 HL 070613NHLBI NIH HHS R01 HL070613NIAID NIH HHS R01 AI 061469NIAID NIH HHS R01 AI061469
6 · The paper itself

Abstract

Cardiac transplantation is an effective treatment for multiple types of heart failure refractive to therapy. Although immunosuppressive therapeutics have increased survival rates within the first year posttransplant, chronic rejection (CR) remains a significant barrier to long-term graft survival. Indicators of CR include patchy interstitial fibrosis, vascular occlusion and progressive loss of graft function. Multiple factors have been implicated in the onset and progression of CR, including TGFbeta, IL-6 and connective tissue growth factor (CTGF). While associated with CR, the role of CTGF in CR and the factors necessary for CTGF induction in vivo are not understood. To this end, we utilized forced expression and neutralizing antibody approaches. Transduction of allografts with CTGF significantly increased fibrotic tissue development, though not to levels observed with TGFbeta transduction. Further, intragraft CTGF expression was inhibited by IL-6 neutralization whereas TGFbeta expression remained unchanged, indicating that IL-6 effects may potentiate TGFbeta-mediated induction of CTGF. Finally, neutralizing CTGF significantly reduced graft fibrosis without reducing TGFbeta and IL-6 expression levels. These findings indicate that CTGF functions as a downstream mediator of fibrosis in CR, and that CTGF neutralization may ameliorate fibrosis and hypertrophy associated with CR.

Indexed as

AnimalsAntibodies, NeutralizingConnective Tissue Growth FactorDisease ProgressionFemaleFibrosisGraft SurvivalHeartHeart TransplantationInterleukin-6MiceMice, Inbred BALB CMice, Inbred C57BLTransforming Growth Factor betaAntibodies, NeutralizingConnective Tissue Growth FactorInterleukin-6Transforming Growth Factor beta

Identifiers

PMID19788504
PMCPMC2860022
OpenAlexW1993577458

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.